NCT06236880Recruiting
A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD
A Phase 2a Study to Evaluate the Safety and Tolerability of Two Repeated Doses of GM-2505 at a 2-Week Interval in Patients With Major Depressive Disorder.
Gilgamesh PharmaceuticalsPhase 2ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Major Depressive Disorder
- Drug/Device/Intervention
- GM-2505
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Gilgamesh Pharmaceuticals
- Location
- Manchester, United Kingdom
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Jan 31, 2024
- End date
- Jul 29, 2024
- Enrollment
- 40 participants
Primary outcome
Safety and Tolerability
Summary
The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and
 preliminary antidepressant efficacy.
ICD-10 classifications
Recurrent depressive disorderRecurrent depressive disorder, unspecifiedDepressive conduct disorderOther recurrent depressive disordersRecurrent depressive disorder, current episode moderate
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06236880
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06236880 through Pure Global AI's free database. This Phase 2 trial is sponsored by Gilgamesh Pharmaceuticals and is currently Recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.